PBAC's latest decision on Ezetimibe and rosuvastatin: Recommended with restriction (2013). Considered for Treatment of hypercholesterolaemia in patients with inadequate cholesterol control on statin monotherapy and specified cardiovascular risk factors or familial hypercholesterolaemia, in combination with dietary therapy and exercise.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2013
Submissions
1
2013 → 2013
Eligible population
Adults with hypercholesterolaemia inadequately controlled with statin monotherapy and having at least one of: coronary heart disease, family history of coronary heart disease, diabetes mellitus, peripheral vascular disease, heterozygous familial hypercholesterolaemia, symptomatic cerebrovascular disease, or hypertension; treated in conjunction with dietary therapy and exercise.